BMS, Samsung BioLogics enter 10-year manufacturing deal

Bristol-Myers Squibb has announced a 10-year manufacturing agreement with Korea-based Samsung BioLogics. Financial terms were not disclosed.

Under terms of the agreement, Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.

"We are pleased to announce this strategic manufacturing relationship with Bristol-Myers Squibb and look forward to delivering best-in-class manufacturing services with the highest global quality standards. The relationship with Bristol-Myers Squibb represents the validation of our long-term commitment to the biopharmaceutical manufacturing industry."

Tae-Han Kim, president and CEO of Samsung BioLogics.

Technology transfer and trial production will begin during July 2013 and commercial production will immediately begin following regulatory approvals.

"Our agreement with Samsung is an important part of our company's overall manufacturing and supply strategy focused on creating long-term relationships with high quality manufacturing partners around the world. This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products."

Louis Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb.